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ABSTRACT
Background: We have already reported that antigen-specific IgG1 antibody production in WBB6F1-WWv
(WWv) mice after oral administration of ovalbumin (OVA) was extremely high. Active systemic anaphylaxis
(ASA) was induced in these mice after intraperitoneal (i.p.) administration of OVA, and Th2-dominant helper T-
cell activation occurred. In this study, we examined the effect of CpG oligodeoxynucleotide (ODN) conjugation
of OVA on oral immunization of WWv mice.
Methods: WWv mice were sensitized by administration of 0.1 mg OVA or CpG ODN-OVA by gavage every
day for 4 weeks, and the serum titers of OVA-specific IgG1, IgE, and IgG2a antibody were determined. ASA
was induced by i.p. injection of OVA, and the changes in body temperature were monitored. In vitro production
of Th1- and Th2- type cytokines by splenocytes re-stimulated with antigen was also measured．
Results: The antigen-specific IgG1 antibody titer in the CpG ODN-OVA-sensitized WWv mice was lower than
in the OVA-sensitized group, but the IgG2a titer was higher. ASA was not induced by i.p. OVA challenge. There
were significant increases in the production of Th1-type cytokine (IFN-γ) by splenocytes in the CpG ODN-OVA-
sensitized mice, but the Th2-type cytokine (IL-4) level in the splenocyte culture medium was lower．
Conclusions: These results indicated that oral administration of CpG ODN-OVA conjugate significantly in-
duced antigen-specific Th1 responses and reduced Th2 responses (allergic reactions) on re-stimulation. These
findings suggest that CpG ODN-antigen conjugate may be useful as an oral vaccine．
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INTRODUCTION
Mucosal immunization is characterized by oral and
nasal immunization and is known to effectively in-
duce both antigen-specific mucosal and systemic im-
mune responses. Therefore , oral or nasal vaccines
may be useful in preventing and curing allergy and
infection. Oral immunization seems to be superior to
immunization by injection in terms of convenience
and safety．
Oligodeoxynucleotides (ODN) containing unmeth-
ylated CpG motifs (5’-Pu-Pu-CpG-Pyr-Pyr-3’) have re-
cently been reported to activate host defense mecha-
nisms inducing innate and acquired immune re-
sponses.1 CpG ODN directly stimulates cells that ex-
press Toll-like receptor (TLR) 9, including macro-
phages and other antigen-presenting cells (APCs) .
Consequently the cells secrete type 1 cytokines, such
as IFNs and IL-12, which cause naïve T cells to differ-
entiate into Th1 cells.2 Recognition of CpG motifs re-
quires TLR9,3 which triggers the induction of cell-
signaling pathways, including mitogen-activated pro-
tein kinases (MAPKs) and NFκB.4
Several study groups have conducted research on
the application of CpG ODNs in the suppression of al-
lergy,5 and many reports ascribe the etiology of al-
lergy to disruption of the balance between Th1- and
Th2-T cells and a Th2-dominant state.6 Thus, allergic
symptoms may be controllable, if the Th-balance is
shifted to Th1 dominance.7 Shirota et al. found that a
conjugate between CpG ODN and antigen (Ag) inhib-
ited airway eosinophilia 100-fold more efficiently than
a mixture of unconjugated CpG and the Ag.8 Admini-
stration of CpG ODN alone may cause nonspecific
Allergology International. 2006;55:43-48
ORIGINAL ARTICLE
1Division of Biochemistry and Immunochemistry and 2Division of
Food, National Institute of Health Sciences, Tokyo, Japan.
Correspondence: Dr. Reiko Teshima, Division of Biochemistry and
Immunochemistry, National Institute of Health Sciences, 1−18−1
Kamiyoga, Setagaya-ku, Tokyo 158−8501, Japan.
Email: rteshima@nihs.go.jp
Received 31 January 2005. Accepted for publication 5 July 2005.
2006 Japanese Society of Allergology
Allergology International Vol 55, No1, 2006 www.jsaweb.jp 43
Fig. 1 Changes in body temperature of antigen-sensitized WBB6F1-W/Wv mice after sys-
temic immunization. Body temperature was monitored at 1-minute intervals after OVA 
chalenge. Each value represents the mean for 7 mice. ＊ ,＊＊ Significant diference from 
the control by Student’ st-test at p＜0.05 and p＜0.01, respectively.
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Th1-like activation and a toxic effect．
We succeeded in inducing antigen-specific anti-
body production without any adjuvant by administer-
ing 0.1 mg or 1.0 mg OVA orally for 9 weeks daily,
and we induced ASA by intraperitoneal (i.p.) injection
of antigen.9 WWv mice proved to be a good model
for studying induction of food allergy, because their
antigen-specific antibody titer has been shown to be
much higher than those in other mice (BALBc ,
B10A etc).10,11 WWv mice have mutations in the c-
kit gene and exhibit defects or deficits in mast cells,
erythrocytes, and interstitial cells of cajal, which ex-
press c-kit protein naturally.12,13 The results also sug-
gest that the high susceptibility of the WWv mice is
attributable to a decrease in c-kit-positive cells andor
TCRγδ-T cells (submitted)．
We, therefore , assessed the possibility of using
CpG ODN-OVA as an oral vaccine in WWv mice.
The CpG ODN conjugated to OVA was administered
orally to the WWv mice, and they were examined for
induction of Th1 responses and suppression of aller-
gic reactions.
METHODS
ANIMALS
Female WBB6F1-WWv (6 weeks) mice were pur-
chased from Japan SLC (Shizuoka, Japan) and main-
tained under pathogen-free conditions in our animal
facility for 1 week before use. The mice were handled
in accordance with NIHS Animal Care and Use
Guidelines．
CPG AND NON-CPG ODN
The CpG ODN used throughout this study consisted
of 20 bases containing two CpG motifs (5 ’ -TCCAT
GACGTTCCTGACGTT-3’).14 The control ODN was
identical except that the CpG motifs were rearranged
(5’-TCCATGAGCTTCCTGAGCTT-3’). Phos-
phorothioate ODNs were synthesized by TaKaRa
Biomedicals (Shiga, Japan). ODN was thiolated for
conjugation. The LPS content of the ODN was <200
pg LPSmg of DNA, as measured by the Limulus HS-
J Single Test (Wako Pure Chemicals, Osaka, Japan)．
DIRECT CONJUGATION OF ODN TO OVA
ODN was conjugated to OVA by mixing thiolated
ODN with maleimide-activated OVA (PIERCE, IL ,
USA)at 4℃ overnight . The molar ratio of CpG to
OVA in the conjugate was calculated to be 6：1. The
molar ratio of non-CpG ODN：OVA was calculated to
be 4.6：1．
IMMUNIZATION AND INDUCTION OF ACTIVE
SYSTEMIC ANAPHYLAXIS (ASA)
Mice were sensitized by daily administration of 0.1
mg OVA (grade V, Sigma Chemical Co, St Louis ,
MO, USA), CpG ODN-OVA or non-CpG ODN-OVA
by gavage for 4 weeks, and ASA challenge was per-
formed by i.p. injection of 1.0 mg of OVA 1 day later.
Body temperature changes associated with ASA were
monitored with a rectal thermometer for mice (Shi-
baura Electronics Co. Ltd., Japan) without general an-
esthesia．
ANTIBODY (IGE, IGG1, AND IGG2A) TITER DE-
TERMINATION
The serum titers (reciprocal of serum dilution with
fluorescence intensity at 50% of the maximum level)
of OVA-specific IgE , IgG1 and IgG2a were deter-
mined by a previously reported method. 9 A 50 μL
volume of OVA (40 μgmL) in 50 mM sodium car-
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Fig. 2 Cytokine production by splenocytes from antigen-
sensitized WBB6F1-W/Wv mice after systemic immunization. 
Splenocytes were isolated from WBB6F1-W/Wv mice oraly 
sensitized with antigen after i.p. sensitization with 1.0 mg of 
OVA. (a) IL-4 and (b) IFN-γ cytokine production by spleno-
cytes was measured as described in the Methods section. 
Each value represents the mean±S.D. for 7 mice. ＊Signifi-
cant diference from the control by Student’ s t-test at p＜
0.05.
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bonate buffer, pH 9.6, was added to each well of a 96-
well microtiter plate , and the plate was incubated
overnight at 4℃. The solutions were discarded, and
each well was washed 4 times with 200 μL PBS con-
taining 0.05% Tween 20 (PBSTween). To minimize
the nonspecific binding of serum proteins to unoccu-
pied solid-phase sites, 200 μL of 0.1% casein in PBS
was added and the plates were incubated for 1 hour
at room temperature . The casein solution was re-
moved, and each well was washed in the same man-
ner as above. Fifty μL of the diluted serum containing
OVA-specific antibodies were added to each well, and
the plates were incubated for 20 hours at 4℃. The so-
lutions were removed, and each well was washed .
Fifty μL of rabbit anti-mouse IgE, IgG1, and IgG2a
(10−3 dilution in PBS containing 0.1% casein (Nordic
Immunology, Tilburg, the Netherlands) ) were added
to each well, and the plates were incubated for 1 hour
at room temperature. The solution in each well was
removed and washed . Fifty μL of β-galactosidase-
linked goat anti-rabbit Ig conjugate (10−3 dilution in
PBS containing 0.1% casein, (Amersham Pharmacia
Biotech, Uppsala, Sweden) ) were added to each well,
and the plates were incubated for 1 hour at room tem-
perature. The antibody-enzyme conjugate solution in
each well was removed and washed. The wells were
incubated for 1 hour at 37℃ with 100 μL PBS contain-
ing 0.1 mM 4-methylumbelliferyl-β-galactoside
(Sigma). Finally, 25 μL of 1 M sodium carbonate was
added to each well. The fluorescence intensity of the
liberated 4-methylumbelliferone was monitored at
317 and 374 nm for excitation and emission, respec-
tively, by a Titertek Fluoroscan reader (Flow Labora-
tories Inc., Costa Mesa, CA, USA)．
CYTOKINE ASSAYS OF SPLENOCYTES
Spleen cells were collected from the OVA-immunized
mice (5 mice per group), and the cells (5×106 cells
ml) were re-stimulated with OVA in vitro at a final
concentration of 100 μgmL in a 24-well culture plate
at 37℃ for 3 days.15 The levels of IL-4, IL-5, IL-12 (p
70), and IFN-γ in the culture medium (RPMI 1640) af-
ter 3 days of co-culture with OVA were measured
with an OptEIA mouse cytokine ELISA set (PharMin-
gen). Absorbance was measured at 450 nm with a mi-
croplate reader (EL 340, Bio-Tek Instruments , Wi-
nooski, VT, USA)．
ISOLATION OF MOUSE IELS
IELs were isolated as previously described by Naga-
fuchi.16 In brief, the small intestine (duodenum, jeju-
num, and ileum) was removed from the mice, and the
small intestine was turned inside-out using polyethyl-
ene tubing. Each reversed intestine was cut into four
segments, and the segments were placed in a conical
50-mL polypropylene tube containing 45 mL of
Hanks’ balanced salt solution (HBSS)(GIBCO) con-
taining 5% FBS (Sigma chemical Co). The tube was
shaken at 37℃ for 45 minutes (horizontal position on
an orbital shaker at 135 rpm), and the cell suspension
was passed through a glass-wool column to remove
adherent cells. The cells were then suspended in 30%
(wtvol) Percoll (Amersham Pharmacia Biotech) and
centrifuged for 20 minutes at 1800 rpm. The cell pel-
let was collected;IELs were purified by density gradi-
ent centrifugation using Percoll as the separation me-
dium (1800 rpm, 20 min);and IELs were recovered at
the 44% and 70% Percoll interphase. More than 90% of
the IELs were recovered．
FLOW CYTOMETRY (FCM)
Two-color or three-color analysis of spleen and IEL
subsets was performed. The antibodies used for FCM
were phycoerythrin (PE)-labeled anti-mouse CD8α
( 53 − 6.7 ; PharMingen ) , fluorescein isothiocyanate
(FITC)-labeled anti-mouse CD4 (H129.19;PharMin-
gen), peridinin chlorophyll protein (PerCP)-labeled
anti-mouse CD3ε (145−2C11 ;PharMingen) , FITC-
labeled anti-mouse Integrin β7 chain (M293;PharMin-
gen) , PE-labeled anti-mouse TCRγδ (UC7−13D5 ;
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Table 1 Serum OVA-specific antibody of WBB6F1- (＋/＋) mice oraly sensitized with CpG ODN-OVA
ELISA titer
OVA-specific antibody
Non CpG ODN-OVACpG ODN-OVAOVAcontrol
275 ± 318383 ± 1761160 ± 683＊＜ 50IgG1
＜ 501126 ± 1259＜ 50＜ 50IgG2a
＜ 50＜ 5058.5 ± 18.5＜ 50IgE
Values are means ± S.D. of data from seven mice per group.
＊ :Significant diference from the control at p＜0.05
Table 2 Flow cytometric analysis of the IELs of W/Wv mice
non-CpG ODN-
OVA
CpG ODN-OVAOVAcontrol
3.494 ± 2.0252.216 ± 1.4872.867 ± 1.8912.879 ± 1.560sIg ＋ (B cel)
87.95 ± 3.681 91.96 ± 4.411＊88.97 ± 4.12886.28 ± 1.747CD3 ＋β7＋ (T cel)
20.58 ± 5.16126.56 ± 7.17520.89 ± 3.59722.85 ± 3.470CD4＋CD8＋(TCRαβCD4CD8αα)
9.952 ± 3.42614.97 ± 4.42212.22 ± 5.13410.29 ± 4.090CD4＋CD8α－(TCRαβCD4)
36.65 ± 5.05438.57 ± 5.44231.95 ± 6.15832.79 ± 4.202CD8α＋CD8β－(CD8αα)
47.69 ± 6.44546.98 ± 5.88251.07 ± 6.51548.92 ± 3.662CD8α＋CD8β＋(TCRαβCD8αβ)
3.478 ± 1.5312.587 ± 1.0393.002 ± 0.9062.933 ± 0.992TCRαβ－γδ＋(TCRγδ)
87.77 ± 3.15691.93 ± 3.85990.16 ± 3.11585.72 ± 7.520TCRαβ＋γδ－(TCRαβ)
Values are means ± S.D. of (% (gated) data from seven mice per group.
＊: Significant diference from control at p＜0.05.
Santa Cruz Biotechnology, Delaware, CA, USA), PE-
labeled anti-mouse TCRγδ (GL3;Immunotech, Mar-
seille , France ) , FITC-labeled anti-mouse TCRαβ
(H57−597;Immunotech), PerCP-labeled anti-mouse
CD4 (H129.19;PharMingen), and FITC-labeled anti-
mouse CD8β (53−5.8;PharMingen) antibodies. All in-
cubations were performed in the dark. A single cell
suspension of lymphocytes in PharMingen Stain
Buffer containing 2% FBS was incubated with 50 μL of
properly diluted mAb at 4℃ for 30 min. The cells
were washed in HBSS by centrifugation , and after
staining, a total of at least 10,000 cells was analyzed
with a FACS Calibur (Becton Dickinson, Sunnyvale,
CA, USA). The data were analyzed with CellquestⓇ
software.
STATISTICAL ANALYSIS
All values are expressed as means ± standard devia-
tion of the mean. Statistical comparisons were per-
formed with Student’s t -test or Mann-Whitney’s U -
test. Each experiment was repeated at least twice．
RESULTS
Antibody production in CpG ODN-OVA- or OVA-
sensitized mice was investigated by measuring the
serum titer of OVA-specific IgG1, IgE, and IgG2a anti-
body of each mouse by indirect ELISA (Table 1) .
There were marked rises in specific IgG1 antibody
titer (1160 ± 683) in the OVA-sensitized mice, and the
IgE antibody titer also rose slightly. In the CpG ODN-
OVA-sensitized WWv mice, on the other hand, the
antigen-specific IgG1 antibody titer (383 ± 176) was
lower than that in the OVA-sensitized group, while
IgG2a titer (1126 ± 1259) was higher than that (<50)
in the OVA-sensitized group. OVA-specific IgA anti-
body titer, which is a marker of mucosal immunity,
was slightly increased in the OVA-sensitized mice
(unpublished data)．
The body temperature of the sensitized mice was
measured at 1-minute intervals for 10 minutes after
the i.p. challenge (systemic immunization) with 1.0
mg of OVA (Fig . 1). Gradual decreases were ob-
served in the OVA- and non-CpG ODN-OVA-
sensitized mice, and the decreases in the body tem-
perature in both groups of mice at 600 seconds after
i.p. OVA immunization were significant in compari-
son with the control mice . The hypothermia con-
firmed the induction of ASA. However, there were no
significant changes in body temperature in the CpG
ODN-OVA-sensitized mice at 600 seconds after
i.p. OVA immunization．
Figure 2 shows the in vitro production of cytokines
by splenocytes re-stimulated with 100 μg of OVA .
There were significant rises in the production of Th2-
type cytokines (e.g., IL-4) by the splenocytes from
the OVA- and non-CpG ODN-OVA-sensitized mice
(Fig. 2a), whereas the Th1-type cytokine (IFN-γ) lev-
els in the splenocyte culture media increased in the
CpG ODN-OVA-sensitized group (Fig. 2b). These re-
sults suggested that oral sensitization with the CpG
ODN-OVA conjugate resulted in a state of Th 1-
dominant helper T-cell activation．
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The duodenum, jejunum, and ileum were excised
from antigen-sensitized mice, and IELs were isolated.
The population of IELs from each group was analyzed
by FCM (Table 2). Only total T cells increased
slightly as a proportion of IELs in the CpG ODN-
OVA-sensitized mice , and the populations of other
cells were almost the same as in the control mice .
The populations of IELs in the OVA-sensitized group
and the non-CpG ODN-OVA-sensitized group were al-
most the same as in the control mice．
DISCUSSION
Several reports have described suppression of the al-
lergic reaction in mice by subcutaneous or i.p , ad-
ministration of CpG ODN combined with antigen,17,18
and Shirota showed that inhalation of CpG ODN-OVA
conjugate inhibits airway eosinophilia in OVA-
sensitized mice.8 Another report claimed that, when
the CpG ODN-antigen conjugate is given to Amb a1-
sensitized mice intraperitoneally , the Th1 reaction
was induced and the antigen-specific IgE antibody
titer did not increase after additional administration of
Amb a1.19 However, there have been no reports of
oral administration of CpG ODN-antigen conjugate
causing suppression of the allergic reaction．
In this study, we conjugated CpG ODN with the an-
tigen and administered it orally to mice. The CpG-B
ODN with nuclease-resistant phosphorothioate (PS)
backbones, which were used in this study, has dra-
matically enhanced B-cell-stimulating properties and
stability compared to CpG-A ODN with phosphodi-
ester (PO) backbones. CpG-B ODN stimulates NK
cells and induces IFN-γ secretion, although the de-
gree of stimulation is weaker than by use with CpG-A
ODN.20,21 CpG ODN might give rise to adverse ef-
fects , because it causes antigen-non-specific reac-
tions. Therefore, we produced the CpG ODN-antigen
conjugate to reduce the adverse effects of the
antigen-non-specific reactions of CpG ODN and inves-
tigated whether it can induce antigen-specific Th1 ac-
tivity．
Table 1 shows that the antigen-specific IgG1 (Th2-
like) antibody titer in the CpG ODN-OVA-sensitized
WWv mice was lower than in the OVA-sensitized
group, whereas the IgG2a (Th1-like) titer was higher,
and there were significant rises in the production of
Th1-type cytokine (IFN-γ) by splenocytes in the CpG
ODN-OVA-sensitized mice. On the other hand, the
Th2-type cytokine (IL-4) level in the splenocyte cul-
ture medium decreased (Fig. 2). Th2-type lympho-
cytes produce cytokines (IL-4, IL-5, etc.) in response
to the antigenic peptide presented on the antigen-
presenting cells (APCs). These cytokines activate in-
flammatory cells, such as mast cells and eosinophils,
and eventually cause allergy. Th1 cells, on the other
hand, have the ability to suppress cytokine produc-
tion by Th2 cells. Many reports ascribe the develop-
ment of allergy to the disruption of the balance be-
tween Th 1-and Th 2-T cells and a Th 2-dominant
state .6 We demonstrated that the CpG ODN-OVA
conjugate orally administered to WWv mice altered
the Th1Th2 balance by inducing strong Th1 re-
sponses. The slight increase of total T cells in a pro-
portion of IELs in the CpG ODN-OVA-sensitized mice
was observed (Table 2). This might reflect the stimu-
latory effect of CpG-ODN-OVA on Th1 cells．
Allergen immunotherapy is associated with a risk
of anaphylaxis, and it is important to prevent anaphy-
laxis for the creation of good vaccines. Our experi-
mental OVA sensitization conditions (dose and pe-
riod) are generally strong enough to induce ASA and
to induce shock on antigen provocation (Fig. 1). How-
ever, ASA was slightly inhibited in the CpG ODN-
OVA conjugate-administered mice, and almost no hy-
pothermia was observed, the same as in the control.
Horner reported finding that the intradermal or intra-
venous administration of CpG ODN-antigen conju-
gate to mice reduced the possibility of anaphylactic
shock,22 and since our study showed that oral ad-
ministration of CpG ODN-antigen reduced anaphy-
laxis reactions , the CpG ODN-antigen conjugate
seems to be useful as an oral vaccine. Especially, the
oral administration of CpG ODN antigen seems to be
applicable to food-derived sensitivity, such as food al-
lergy or celiac disease．
The mechanism of action of the CpG ODN-antigen
conjugate has not been examined in detail . Shirota
proposed the following hypothesis.8 The APCs sur-
rounded by CpG ODN-OVA present the antigenic
peptide on their membrane surface and simultane-
ously secrete IL-12. The anti-OVA Th cells recognize
antigen peptides on APCs , approach APCs very
closely, and become an effective target for IL-12. The
effect of the CpG ODN is then concentrated on T
cells specific for the antigen combined with CpG
ODN, and an antigen-specific reaction occurs. These
IL-12-induced Th1 cells weaken the effect of Th2
cells, and the antigen-specific allergy reactions are in-
hibited．
As intraperitoneal injection with Amb a1-CpG con-
jugate to Amb a1-sensitized mice induced a de novo
Th-1 response and suppressed IgE antibody forma-
tion after additional challenge with Amb a1.19 Oral
administration of OVA-CpG to OVA immunized mice
might suppress IgG1 or IgE antibody production af-
ter additional challenge with OVA．
In conclusion, we conjugated CpG ODN to OVA
and succeeded in inducing antigen-specific Th1 reac-
tions by oral administration to WWv mice. The CpG-
ODN-OVA conjugate seems to be useful as an oral
vaccine．
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